Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase

Clinical and Experimental Immunology

Volumn 183, Issue 3, 2016, Pages 480-489

  Barros, P O ^a   Cassano, T ^a   Hygino, J ^a   Ferreira, T B ^a   Centuriao N ^a   Kasahara, T M ^a   Andrade, R M ^a   Linhares, U C ^a   Andrade, A F B ^b   Vasconcelos, C C F ^a   Alvarenga, R ^a   Marignier, R ^c   Bento, Cleonice A M ^a  

^a Federal University of the State of Rio de Janeiro   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

Author keywords

IL 10; IL 21; IL 6; IL 6R signalling; Neuromyelitis optica

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; HYDROCORTISONE; IL10 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MONOCYTE; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; TH17 CELL; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEUROMYELITIS OPTICA; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECEPTORS, INTERLEUKIN-6; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TH17 CELLS;

EID: 84958999087     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12733     Document Type: Article

References (37)

1. Wingerchuk D, Lennon V, Lucchinetti C et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805-15.
2. Jarius S, Franciotta D, Paul F et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflamm 2010; 7:52
3. Kira J, Yamasaki K, Horiuchi I et al. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999; 166:53-7.
4. Marrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care 2013; 15:113-8.
5. Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002; 73:429-35.
6. Pohl M, Kawakami N, Kitic M et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol Commun 2013; 1:85.
7. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 118:209-17.
8. Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125:1450-61.
9. Lefkowitz D, Angelo JN. Neuromyelitis optica with unusual vascular changes. Arch Neurol 1984; 41:1103-5.
10. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72:53-64.
11. Ishizu T, Osoegawa M, Mei F-J et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128:988-1002.
12. Uzawa A, Mori M, Arai K et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16:1443-52.
13. Wu A, Zhong X, Wang H et al. Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis. Can J Neurol Sci 2012; 39:813-20.
14. Xu W, li R, Dai Y et al. IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2013; 261:87-91.
15. Linhares UC, Schiavoni PB, Barros OB et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013; 33:179-89.
16. Kira JL. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiol 2011; 18:69-79.
17. Kieseier BC, Stüve O, Dehmel T et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013; 70:390-3.
18. Araki M, Matsuoka T, Miyamoto K et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study. Neurology 2014; 82:1302-6.
19. Wingerchuk DM, Lennon VA, Pittock SJ et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-9.
20. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5:1731-40.
21. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
22. Segura E, Touzot M, Bohineust A et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013; 38:336-48.
23. + T cells. Arthritis Res Ther 2009; 11:257.
24. Qu N, Xu M, Mizoguchi I et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol 2013; 2013:968549.
25. Korn T, Mitsdoerffer M, Croxford AL et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105:18460-5.
26. Goodman WA, Levine AD, Massari JV et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183:3170-6.
27. Wang P, Zheng SG. Regulatory T cells and B cells: implication on autoimmune diseases. Int J Clin Exp Pathol 2013; 6:2668-74.
28. Deenick K, Tangye SG. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol 2007; 285:503-5.
29. Monteleone G, Pallone F, Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009; 20:185-91.
30. Liu SM, King C. IL-21-producing Th cells in immunity and autoimmunity. J Immunol 2013; 191:3501-6.
31. Chihara N, Aranami T, Sato W et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108:3701-6.
32. Watanabe S, Nakashima I, Misu T et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13:128-32.
33. Schmitz ML, Bacher S, Dienz O. NF-kappaB activation pathways induced by T cell costimulation. FASEB J 2003; 17:2187-93.
34. De Kloet CS, Vermetten E, Bikker A et al. Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder. Mol Psychiatry 2007; 12:443-53.
35. Gotovac K, Sabioncello A, Rabatic S et al. Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in individuals with post-traumatic stress disorder (PTSD). Clin Exp Immunol 2003; 131:335-9.
36. Matysiak M, Makosa B, Walczak A et al. Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult Scler 2008; 14:919-26.
37. Gold SM, Sasidhar MV, Lagishetty V et al. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. J Clin Endocrinol Metab 2012; 97:E1402-10.